- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04669808
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Localized Injection of STP705 in Adult Patients With Basal Cell Carcinoma
This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC).
Goals:
- To determine the safe and effective recommended dose of STP705 for the treatment of basal cell carcinoma.
- Analysis of biomarkers common to BCC formation pathway including TGF-β1 and COX-2.
Study Overview
Detailed Description
Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as head and neck. The most commonly found clinical feature of Basal Cell Carcinoma (BCC) is an elevated tumor with a pearly and translucent margin and telangiectasia. The color may vary widely from nearly normal skin color to erythematous to violaceous and may also be pigmented. BCC may also resemble noncancerous skin conditions such as eczema or psoriasis. The majority of these cancers occur on areas of skin that are regularly exposed to sunlight or other ultraviolet radiation.
The STP705 drug substance (STP705) is composed of two siRNA oligonucleotides, targeting the expression of TGF-β1 and Cox-2 mRNA respectively. Along with the HKP-enhanced delivery system, the combination is expected to downregulate TGF-β1 and COX-2 expression resulting in the inhibition of tumor growth and provide an alternative non-invasive approach for the treatment of BCC.
This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with BCC. This study seeks to establish a safe and effective recommended dose of STP705 for the treatment of BCC. The clinician will evaluate the change in tumor size at each treatment visit. At the End of Treatment visit, the residual tumor, or former tumor location, will be excised for analysis. Expression of biomarkers common to the BCC formation pathway, including TGF-β1 and COX-2, will be evaluated.
Safety and tolerability will be assessed by the number of incidence of adverse events (AEs) and serious adverse events (SAEs); the incidence of AEs and SAEs leading to discontinuation of trial medication; the incidence and severity of Local Skin Response (LSR); hypopigmentation and hyperpigmentation following treatment; and the tolerability of repeated localized administration of STP705 as assessed by investigator-evaluation of injection site reactions for all patients and within each cohort.
The study plans to enroll approximately 35 adult patients at up to 3 clinical sites in the United States. The 35 patients will be divided equally among 7 cohorts (30, 60, 90, 120, 180, 240, and 320 μg dose level) of 5 patients each.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Nadia Sheibani, MPH
- Phone Number: (301) 7401730
- Email: nadiasheibani@sirnaomics.com
Study Locations
-
-
Florida
-
Aventura, Florida, United States, 33180
- Center for Clinical and Cosmetic Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria: Subjects are required to meet all of the following criteria for enrollment into the study:
- Male or female adult ≥ 18 years of age.
- Primary, histologically confirmed trunk or extremity (non-peri-orbital/-anogenital/-facial/-scalp) basal cell carcinoma lesion suitable for excision with a minimum diameter of 0.5 cm and with a maximum diameter of 2.0 cm.
- Histological diagnosis made no more than 6 months prior to the screening visit.
- Histological biopsy removed ≤25% of the original volume of the target lesion.
- No other dermatological disease in the BCC target site or surrounding area, which in the opinion of the investigator, could interfere with the study.
- Willing to refrain from using non-approved lotions or creams on the target site and surrounding area during the treatment period.
- Willing to refrain from exposure to excessive direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study.
- Laboratory values for the tests (listed in the Study Schedule) within the reference ranges as defined by the central laboratory, or "out of range" test results that is clinically acceptable to the investigator. Ability to follow study instructions and likely to complete all study requirements.
- Written informed consent obtained, including consent for tissue to be examined and stored by the Central Histology Lab.
- Written consent to allow photographs of the target BCC lesion to be used as part of the study data and documentation.
- For females of childbearing potential, a negative pregnancy test at screening and using an acceptable form of birth control (oral / implant/ injectable/ transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy).
Exclusion Criteria:
- Pregnant or lactating.
- Presence of known or suspected systemic cancer.
- Histological evidence of SCC, or any other non-BCC tumor in the biopsy specimen.
- Histological evidence of infiltrative or other aggressive histological subtype growth patterns in the biopsy specimen.
- History of recurrence of the target BCC lesion.
- Evidence of dermatological disease or confounding skin condition with in 2 cm margin of the target BCC lesion, e.g., SCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema, xeroderma pigmentosa.
- Concurrent disease or treatment that suppresses the immune system;
- Patients with baseline QTC > 480 msec using Frederica's formula.
- Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk.
- Known sensitivity to any of the ingredients in the study medication.
- Use of a tanning beds or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the study.
- Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit.
- Use of systemic retinoids within the 6 months prior to the screening period.
- Treatment with systemic immunomodulators or immunosuppressants within the 6 months prior to the screening period.
- Use of topical immunomodulators within 2 cm of the target BCC lesion within the 4 weeks prior to the screening period.
- Treatment with the following topical agents within 2 cm of the target BCC lesion within the 4 weeks prior to the screening visit: amino-levulinic acid, 5-fluorouracil, corticosteroids, retinoids, diclofenac, ingenol mebutate, or imiquimod.
- Treatment with liquid nitrogen, surgical excision (excluding diagnostic incisional biopsy) or curettage within 2 cm of the target BCC lesion during the 4 weeks prior to the screening visit.
- Evidence of current chronic alcohol or drug abuse.
- Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of the screening visit.
- In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study.
- Taking any other investigational product within 1 month of first dose of STP705.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A: STP705 30 μg dose
Cohort A: STP705 30 μg dose, localized injection, given once a week for 6 weeks
|
Dry powder for intra-and peri-lesional injection.
Other Names:
|
Experimental: Cohort B: STP705 60 μg dose
Cohort B: STP705 60 μg dose, localized injection, given once a week for 6 weeks
|
Dry powder for intra-and peri-lesional injection.
Other Names:
|
Experimental: Cohort C: STP705 90 μg dose
Cohort C: STP705 90 μg dose, localized injection, given once a week for 6 weeks
|
Dry powder for intra-and peri-lesional injection.
Other Names:
|
Experimental: Cohort D: STP705 120 μg dose
Cohort D: STP705 120 μg dose, localized injection, given once a week for 6 weeks
|
Dry powder for intra-and peri-lesional injection.
Other Names:
|
Experimental: Cohort E: STP705 180 μg dose
Cohort E: STP705 180 μg dose, localized injection, given once a week for 6 weeks
|
Dry powder for intra-and peri-lesional injection.
Other Names:
|
Experimental: Cohort F: STP705 240 μg dose
Cohort F: STP705 240 μg dose, localized injection, given once a week for 6 weeks
|
Dry powder for intra-and peri-lesional injection.
Other Names:
|
Experimental: Cohort G: STP705 320 μg dose
Cohort G: STP705 320 μg dose, localized injection, given once a week for 6 weeks
|
Dry powder for intra-and peri-lesional injection.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with histological clearance of treated basal cell carcinoma lesion at the End of Treatment (EOT)
Time Frame: 6 weeks
|
Histological clearance (HC) will be defined as the absence of detectable evidence of BCC tumor cell nests as determined by central pathology review.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in clinical diameter of the treated basal cell carcinoma lesion over the 6 week treatment period
Time Frame: over the 6 week treatment period
|
A base line assessment of lesion clinical diameter will be made by investigator at T1 (first visit).
The change in size will be assessed every week until the surgical excision of BCC at the End of Treatment (EOT) visit.
|
over the 6 week treatment period
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark Nestor, MD, PhD, Center for Clinical and Cosmetic Research
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SRN-705-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Cell Carcinoma
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | BCC | BCC - Basal Cell Carcinoma | Basal Cell CancerUnited States
-
MediWound LtdRecruitingNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University of MiamiCompletedNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
Christopher ZacharyRecruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University Hospital, BordeauxCompletedLocally Advanced Basal Cell Carcinoma | Metastatic Basal Cell CarcinomaFrance
-
Seton Healthcare FamilyUniversity of Texas at Austin; Dell Medical School at The University of Texas...WithdrawnBasal Cell Carcinoma (BCC) | Squamous Cell Carcinoma (SCC)
-
Biofrontera Bioscience GmbHActive, not recruitingSuperficial Basal Cell CarcinomaUnited States
-
Maastricht University Medical CenterRadboud University Medical Center; Catharina Ziekenhuis EindhovenCompletedSuperficial Basal Cell CarcinomaNetherlands
-
Maastricht University Medical CenterActive, not recruitingNodular Basal Cell CarcinomaNetherlands
-
Kavita SarinNational Institutes of Health (NIH); Medivir; American Skin AssociationCompletedSkin Basal Cell CarcinomaUnited States
Clinical Trials on STP705
-
SirnaomicsCompletedAbdominal ObesityUnited States
-
SirnaomicsNot yet recruiting
-
SirnaomicsTranslational Drug DevelopmentCompletedHepatocellular Carcinoma | Cholangiocarcinoma | Liver MetastasesUnited States
-
SirnaomicsCompletedFacial isSCCUnited States
-
SirnaomicsCompleted
-
SirnaomicsCompletedSquamous Cell Carcinoma in SituUnited States
-
SirnaomicsAmarex Clinical ResearchCompletedOpen Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCCBowen's Disease | Cutaneous Squamous Cell Carcinoma in SituUnited States
-
SirnaomicsCompletedHypertrophic ScarUnited States
-
Chulalongkorn UniversityRecruiting